Navigation Links
Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building

New Facility Meets LEEDS Standards for Sustainable Development

PLEASANTON, Calif., April 3, 2008 /PRNewswire/ -- Roche Molecular Diagnostics (RMD) today announced the opening of its new research facility at the company's global headquarters in Pleasanton, California. The building represents the final phase of consolidation of RMD's West Coast operations into one campus in Pleasanton which now houses close to 500 employees, including 120 members of RMD's research teams previously located in Alameda. RMD is a world-leading molecular diagnostics company, developing diagnostics designed to provide information allowing healthcare providers to select and monitor patient response to therapy or identify molecular characteristics of a disease. RMD's products also help to ensure the safety of blood and blood products before they are used for medical procedures by using its approved systems to screen donations.

RMD is a world-leading molecular diagnostics company, developing diagnostics that provide information to select the best therapy for a particular patient by enabling physicians to monitor response to treatment or identify molecular characteristics of a disease. RMD also supports the safety of the blood supply by using our approved systems to screen donors.

The research building encompasses more than 135,000 square feet on RMD's 33.4 acre campus in the Hacienda Business Park. Designed by a local firm, DES Architects + Engineers under the leadership of Craig Ivancovich, architect and principal, it was then built by another local company, DPR Construction. The building and its surroundings incorporate numerous features designed to ensure successful green building status, construction and operation, and further demonstrate Roche's ongoing commitment to sustained development and environmental efficiency throughout its global operations. Going forward, RMD is working to implement final operational improvements that will enable the new facility to qualify for Leadership in Energy and Environmental Design (LEED) "green building" certification from the US Green Building Council.

"In designing the new building, it was important to us to minimize our environmental footprint while designing a functional space that could support core research functions and state-of-the-art molecular biology research laboratories," said Daniel O'Day, President and CEO. "With the development of this new building, we have achieved these goals while creating an optimal space for our employees to focus on their ongoing contributions to improving healthcare for people around the world."

About RMD

Headquartered in Pleasanton, California, Roche Molecular Diagnostics is the world leader in molecular in vitro diagnostics. A business area of Roche (Basel, Switzerland), RMD develops and manufactures innovative tests based on its Nobel Prize winning polymerase chain reaction (PCR) technology. PCR is the technology that underlies a new generation of medical diagnostics.

RMD supplies a wide array of innovative medical diagnostic products, services, and technologies to researchers, physicians, patients, hospitals and laboratories worldwide. Our marketed diagnostic tests and automated instrument platforms, and those now in development, are focused on blood screening, virology, microbiology, genomics and oncology, and sexually transmitted diseases. For a complete list of our diagnostics and blood screening products, please visit our website at

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Amy Berry

Roche Molecular Diagnostics


Phone: 925-730-8028


SOURCE Roche Molecular Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
Breaking Biology News(10 mins):